Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise

Dow Jones

2025/11/18

By Kelly Cloonan

Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.

The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.

Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.

The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.

Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 17, 2025 16:20 ET (21:20 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584267461"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584267461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584267461?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584267461","market":"nz","top_or_hot":-1,"title":"Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-18 05:20</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENTA","symbol_name":"Enanta Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584267461","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584267461","pubTimestamp":1763414400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"随着丙型肝炎治疗药物销售额的上升，Enanta Pharmaceuticals第四季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n\n\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n\n\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n\n\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n\n\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 16:20 ET (21:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}